Literature DB >> 15223991

Heterogeneity of diabetes phenotype in patients with 3243 bp mutation of mitochondrial DNA (Maternally Inherited Diabetes and Deafness or MIDD).

P J Guillausseau1, D Dubois-Laforgue, P Massin, M Laloi-Michelin, C Bellanné-Chantelot, H Gin, E Bertin, J F Blickle, B Bauduceau, B Bouhanick, J Cahen-Varsaux, S Casanova, G Charpentier, P Chedin, C Derrien, A Grimaldi, B Guerci, E Kaloustian, F Lorenzini, A Murat, F Olivier, M Paques, V Paquis-Flucklinger, A Tielmans, M Vincenot, B Vialettes, J Timsit.   

Abstract

OBJECTIVE: In patients with maternally inherited diabetes and deafness (MIDD), due to 3 243 A > G mutation of mitochondrial DNA (mtDNA), diabetes may present with variable phenotypes.
OBJECTIVE: To ascertain the existence of two distinct phenotypes, MIDD1 and MIDD2, in a series of patients with MIDD.
DESIGN: Multicenter prospective study. PATIENTS: 77 patients with diabetes and the mtDNA 3243 mutation and 139 control patients with type 1 (T1D) or type 2 (T2D) diabetes, matched according to initial presentation of diabetes, age at onset, sex, and duration of diabetes (24 T1D and 115 T2D, including 55 treated with insulin). MEASUREMENTS: Anthropometric characteristics (height, body weight, body mass index [BMI], sex), family history of diabetes, and characteristics of diabetes (age at onset, treatment, hemoglobin A1c [HbA1c]), extrapancreatic manifestations.
RESULTS: In 13 cases (17%, MIDD1), diabetes presented as insulin-dependent from the onset, with ketoacidosis in 6 cases. In 64 cases (83%, MIDD2), diabetes resembled T2D, and was treated with diet in 12 cases, oral hypoglycemic agents in 21 cases, or insulin in 31 cases. Compared with patients with MIDD2, patients with MIDD1 were characterized by lower age at onset of first manifestation of MIDD (25.4 +/- 9.6 vs 33.7 +/- 13.2 Years, P<0.0005), lower body weight (49.1 +/- 7.4 vs 56.3 +/- 10.9 kg, P<0.0025), lower BMI (18.2 +/- 2.3 vs 20.9 +/- 3.6 kg/m2, P<0.0005), and higher HbA1c levels (9.5 +/- 2.0 vs 7.5 +/- 1.6%, P<0.0005). Frequency of family history of diabetes and of extrapancreatic manifestations was the same in both MIDD subtypes. No difference was found within the MIDD2 subtype when comparing patients treated with or without insulin. Compared with matched controls, patients with MIDD had a lower BMI (MIDD1/T1D 18.2 +/- 2.3 vs 24.0 +/- 3.6 kg/m2 and MIDD2/T2D 20.9 +/- 3.6 vs 30.2 +/- 5.9 kg/m2, P<0.0025). Lastly, male patients with MIDD had a shorter height than controls (MIDD1/T1D: 166.1 +/- 3.2 vs 177.3 +/- 6.6 cm and MIDD2/T2D: 168.4 +/- 7.2 vs 173.6 +/- 6.6 cm P<0.025).
CONCLUSIONS: These results confirm the existence of two different phenotypes in MIDD, MIDD1 and MIDD2, which may be related to the severity of the mitochondrial disease. The role of other genetic and/or environmental factors in the variable phenotype of MIDD remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15223991     DOI: 10.1016/s1262-3636(07)70105-2

Source DB:  PubMed          Journal:  Diabetes Metab        ISSN: 1262-3636            Impact factor:   6.041


  14 in total

Review 1.  Mitochondrial disease and endocrine dysfunction.

Authors:  Jasmine Chow; Joyeeta Rahman; John C Achermann; Mehul T Dattani; Shamima Rahman
Journal:  Nat Rev Endocrinol       Date:  2016-10-07       Impact factor: 43.330

2.  Retinal and renal complications in patients with a mutation of mitochondrial DNA at position 3,243 (maternally inherited diabetes and deafness). A case-control study.

Authors:  P Massin; D Dubois-Laforgue; T Meas; M Laloi-Michelin; H Gin; B Bauduceau; C Bellanné-Chantelot; E Bertin; J-F Blickle; B Bouhanick; J Cahen-Varsaux; S Casanova; G Charpentier; P Chedin; O Dupuy; A Grimaldi; B Guerci; E Kaloustian; A Lecleire-Collet; F Lorenzini; A Murat; H Narbonne; F Olivier; V Paquis-Flucklinger; M Virally; M Vincenot; B Vialettes; J Timsit; P J Guillausseau
Journal:  Diabetologia       Date:  2008-06-26       Impact factor: 10.122

Review 3.  Not quite type 1 or type 2, what now? Review of monogenic, mitochondrial, and syndromic diabetes.

Authors:  Roseanne O Yeung; Fady Hannah-Shmouni; Karen Niederhoffer; Mark A Walker
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

Review 4.  How can we treat mitochondrial encephalomyopathies? Approaches to therapy.

Authors:  Rita Horvath; Grainne Gorman; Patrick F Chinnery
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

5.  Low prevalence of patients with mitochondrial disease in the German/Austrian DPV diabetes registry.

Authors:  Christina Reinauer; Thomas Meissner; Michael Roden; Angelika Thon; Paul-Martin Holterhus; Holger Haberland; Elisabeth Binder; Wolfgang Marg; Esther Bollow; Reinhard Holl
Journal:  Eur J Pediatr       Date:  2015-12-15       Impact factor: 3.183

6.  A family with diabetes and heart failure.

Authors:  Bernhard Gerber; Christine Manser; Peter Wiesli; Christoph A Meier
Journal:  BMJ Case Rep       Date:  2010-10-18

7.  Wild-Type Mitochondrial DNA Copy Number in Urinary Cells as a Useful Marker for Diagnosing Severity of the Mitochondrial Diseases.

Authors:  Hui Liu; Yinan Ma; Fang Fang; Ying Zhang; Liping Zou; Yanling Yang; Sainan Zhu; Songtao Wang; Xuefei Zheng; Pei Pei; Lin Li; Hairong Wu; Yang Xiao; Yufeng Xu; Liwen Wang; Yanyan Cao; Hong Pan; Yu Qi
Journal:  PLoS One       Date:  2013-06-27       Impact factor: 3.240

8.  Mitochondrial diabetes in children: seek and you will find it.

Authors:  Cristina Mazzaccara; Dario Iafusco; Rosario Liguori; Maddalena Ferrigno; Alfonso Galderisi; Domenico Vitale; Francesca Simonelli; Paolo Landolfo; Francesco Prisco; Mariorosario Masullo; Lucia Sacchetti
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

Review 9.  Pathogenesis of the metabolic syndrome: insights from monogenic disorders.

Authors:  Rinki Murphy; Richard W Carroll; Jeremy D Krebs
Journal:  Mediators Inflamm       Date:  2013-05-21       Impact factor: 4.711

Review 10.  Endocrine disorders in mitochondrial disease.

Authors:  Andrew M Schaefer; Mark Walker; Douglass M Turnbull; Robert W Taylor
Journal:  Mol Cell Endocrinol       Date:  2013-06-13       Impact factor: 4.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.